Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT06024174 Terminated - Clinical trials for Advanced Solid Tumors

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Start date: November 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).

NCT ID: NCT06012708 Recruiting - Clinical trials for Advanced Solid Tumors

Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713

Start date: September 11, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of the combination therapy of KN510 and KN713 and determine the MTD and RP2D in patients with advanced solid tumors.

NCT ID: NCT06004245 Recruiting - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors

Start date: January 25, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RO7589831 monotherapy in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. RO7589831 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, RO7589831 may be able to block the growth of these types of cancer.

NCT ID: NCT05976906 Recruiting - Clinical trials for Advanced Solid Tumors

Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, multi-center, phase I study to evaluate the safety, tolerability, preliminary efficacy, pharmacodynamics and immunogenicity of universal chimeric natural killer receptor modified T-cells (CNK-UT) targeting NKG2D-Ligands and NCR2-Ligands with or without lymphodepletion in advanced solid tumors.

NCT ID: NCT05972460 Recruiting - Clinical trials for Advanced Solid Tumors

IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

Start date: August 18, 2021
Phase: Phase 1
Study type: Interventional

This trial is a first-in-human, open-label, multi-center, dose escalation phase 1a study followed by cohort expansion phase 1b study to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced solid tumors.

NCT ID: NCT05954312 Recruiting - Clinical trials for Advanced Solid Tumors

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Start date: July 28, 2023
Phase: Phase 1
Study type: Interventional

A FIH study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VVD-130037 in participants with advanced solid tumors.

NCT ID: NCT05951608 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Start date: July 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors

NCT ID: NCT05949632 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Start date: April 16, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.

NCT ID: NCT05944224 Recruiting - Clinical trials for Advanced Solid Tumors

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Start date: October 17, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.

NCT ID: NCT05942378 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors

Start date: July 1, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label study evaluating the efficacy and safety of HRXG-K-1939 in combination with Adebrelimab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in patients with advanced solid tumors. HRXG-K-1939 will be administered to patients in a dose escalation regimen to determine a recommended dose for expansion.